Ascendis Pharma upgraded by Oppenheimer with a new price target
$ASND
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer upgraded Ascendis Pharma from Perform to Outperform and set a new price target of $180.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/3/2025 | $250.00 | Overweight | Morgan Stanley |
| 5/5/2025 | $250.00 | Equal-Weight → Overweight | Morgan Stanley |
| 4/16/2025 | $205.00 | Outperform | RBC Capital Mkts |
| 1/7/2025 | $196.00 | Buy | UBS |
| 9/5/2024 | $180.00 | Perform → Outperform | Oppenheimer |
| 6/25/2024 | $156.00 → $175.00 | Hold → Buy | TD Cowen |
| 5/31/2024 | $200.00 | Buy | Stifel |
| 12/20/2023 | $150.00 | Buy | Jefferies |
Morgan Stanley resumed coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $250.00
Morgan Stanley upgraded Ascendis Pharma from Equal-Weight to Overweight and set a new price target of $250.00
RBC Capital Mkts initiated coverage of Ascendis Pharma with a rating of Outperform and set a new price target of $205.00
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will present new data from Week 156 of the Company's Phase 3 PaTHway Trial demonstrating the safety and efficacy of long-term treatment with TransCon® PTH (palopegteriparatide) in adults with hypoparathyroidism – including maintenance of serum and urine biochemistries within normal levels and sustained improvement in renal function. Dr. Carlos Bacino will present additional safety and tolerability data from Week 52 of the Company's pivotal Approa
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth - Safety and tolerability data consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well to
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared to placebo, with a safety and tolerability profile similar to placebo – The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition1 COPENHAGEN, Denmark, June 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for priority review its New Dr
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth - Safety and tolerability data consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well to
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 1, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendisphar
– Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million – Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in Q1 2025, followed by MAA in Q3 2025 – SKYTROFA® full year 2024 revenue was ~€202 million, excluding sales deductions related to prior years, (€197.0 million plus ~€5 million of sales deductions related to prior years) – Total 2024 operating expenses of €598 million – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter an
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to
TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company. All matters presented for shareholder approval at the Me
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)